Tejas Savant
Stock Analyst at Morgan Stanley
(2.22)
# 2,678
Out of 4,862 analysts
235
Total ratings
40.88%
Success rate
-4.33%
Average return
Main Sectors:
Stocks Rated by Tejas Savant
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CTKB Cytek Biosciences | Maintains: Equal-Weight | $9 → $7 | $3.22 | +117.39% | 9 | May 28, 2025 | |
| TXG 10x Genomics | Maintains: Overweight | $26 → $18 | $10.42 | +72.83% | 14 | May 19, 2025 | |
| ILMN Illumina | Maintains: Equal-Weight | $136 → $100 | $86.93 | +15.04% | 8 | May 12, 2025 | |
| TEM Tempus AI | Maintains: Overweight | $60 → $65 | $71.28 | -8.81% | 3 | May 9, 2025 | |
| HOLX Hologic | Maintains: Equal-Weight | $77 → $65 | $64.75 | +0.39% | 9 | May 5, 2025 | |
| CYRX Cryoport | Maintains: Equal-Weight | $8 → $7 | $6.68 | +4.79% | 2 | May 5, 2025 | |
| ADPT Adaptive Biotechnologies | Maintains: Equal-Weight | $7 → $9 | $10.32 | -12.79% | 12 | May 5, 2025 | |
| NEO NeoGenomics | Maintains: Equal-Weight | $17 → $10 | $7.07 | +41.44% | 13 | May 1, 2025 | |
| AVTR Avantor | Downgrades: Equal-Weight | $25 → $15 | $13.07 | +14.77% | 17 | Apr 28, 2025 | |
| MRVI Maravai LifeSciences Holdings | Maintains: Equal-Weight | $7 → $5 | $2.13 | +134.74% | 13 | Mar 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $16 → $20 | $41.31 | -51.59% | 2 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $176 → $185 | $165.34 | +11.89% | 13 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $245 → $250 | $156.89 | +59.35% | 11 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $647 → $678 | $402.76 | +68.34% | 14 | Jan 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Equal-Weight | $24 → $23 | $23.48 | -2.04% | 1 | Dec 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $26 → $28 | $26.44 | +5.90% | 13 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $32 → $21 | $5.03 | +317.50% | 2 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $4 → $2 | $1.20 | +66.67% | 13 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $4 → $3 | $1.25 | +140.96% | 10 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $80 → $40 | $8.94 | +347.43% | 2 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $6 | $0.71 | +747.34% | 3 | Aug 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $10 | $2.91 | +243.64% | 8 | May 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $2.75 | $3.58 | -23.18% | 6 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $11 → $5 | $6.01 | -16.81% | 12 | Feb 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $11 → $10 | $2.07 | +383.09% | 10 | Feb 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $80 → $73 | $49.29 | +48.10% | 9 | Feb 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $350 → $250 | $149.45 | +67.28% | 1 | Aug 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $5 | $0.29 | +1,643.98% | 5 | May 12, 2022 |
Cytek Biosciences
May 28, 2025
Maintains: Equal-Weight
Price Target: $9 → $7
Current: $3.22
Upside: +117.39%
10x Genomics
May 19, 2025
Maintains: Overweight
Price Target: $26 → $18
Current: $10.42
Upside: +72.83%
Illumina
May 12, 2025
Maintains: Equal-Weight
Price Target: $136 → $100
Current: $86.93
Upside: +15.04%
Tempus AI
May 9, 2025
Maintains: Overweight
Price Target: $60 → $65
Current: $71.28
Upside: -8.81%
Hologic
May 5, 2025
Maintains: Equal-Weight
Price Target: $77 → $65
Current: $64.75
Upside: +0.39%
Cryoport
May 5, 2025
Maintains: Equal-Weight
Price Target: $8 → $7
Current: $6.68
Upside: +4.79%
Adaptive Biotechnologies
May 5, 2025
Maintains: Equal-Weight
Price Target: $7 → $9
Current: $10.32
Upside: -12.79%
NeoGenomics
May 1, 2025
Maintains: Equal-Weight
Price Target: $17 → $10
Current: $7.07
Upside: +41.44%
Avantor
Apr 28, 2025
Downgrades: Equal-Weight
Price Target: $25 → $15
Current: $13.07
Upside: +14.77%
Maravai LifeSciences Holdings
Mar 25, 2025
Maintains: Equal-Weight
Price Target: $7 → $5
Current: $2.13
Upside: +134.74%
Mar 18, 2025
Maintains: Equal-Weight
Price Target: $16 → $20
Current: $41.31
Upside: -51.59%
Mar 5, 2025
Maintains: Overweight
Price Target: $176 → $185
Current: $165.34
Upside: +11.89%
Feb 11, 2025
Maintains: Overweight
Price Target: $245 → $250
Current: $156.89
Upside: +59.35%
Jan 31, 2025
Maintains: Overweight
Price Target: $647 → $678
Current: $402.76
Upside: +68.34%
Dec 3, 2024
Assumes: Equal-Weight
Price Target: $24 → $23
Current: $23.48
Upside: -2.04%
Nov 18, 2024
Maintains: Underweight
Price Target: $26 → $28
Current: $26.44
Upside: +5.90%
Nov 18, 2024
Maintains: Equal-Weight
Price Target: $32 → $21
Current: $5.03
Upside: +317.50%
Aug 12, 2024
Maintains: Equal-Weight
Price Target: $4 → $2
Current: $1.20
Upside: +66.67%
Aug 6, 2024
Downgrades: Equal-Weight
Price Target: $4 → $3
Current: $1.25
Upside: +140.96%
May 15, 2024
Maintains: Equal-Weight
Price Target: $80 → $40
Current: $8.94
Upside: +347.43%
Aug 3, 2023
Reiterates: Equal-Weight
Price Target: $6
Current: $0.71
Upside: +747.34%
May 10, 2023
Maintains: Overweight
Price Target: $11 → $10
Current: $2.91
Upside: +243.64%
Mar 7, 2023
Reiterates: Equal-Weight
Price Target: $2.75
Current: $3.58
Upside: -23.18%
Feb 27, 2023
Maintains: Equal-Weight
Price Target: $11 → $5
Current: $6.01
Upside: -16.81%
Feb 21, 2023
Maintains: Equal-Weight
Price Target: $11 → $10
Current: $2.07
Upside: +383.09%
Feb 21, 2023
Maintains: Overweight
Price Target: $80 → $73
Current: $49.29
Upside: +48.10%
Aug 4, 2022
Downgrades: Equal-Weight
Price Target: $350 → $250
Current: $149.45
Upside: +67.28%
May 12, 2022
Maintains: Equal-Weight
Price Target: $7 → $5
Current: $0.29
Upside: +1,643.98%